AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05402631 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural Injection
Description: patient receives an epidural injection due to lower back pain
Study NCT05402631 — intervention group
Intervention type: PROCEDURE
Intervention: Periradicular Injection
Description: patient receives a periradicular injection due to lower back pain
Study NCT06515444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 minutes program
Description: The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.
Study NCT06515444 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 10 minutes program
Description: The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.
Study NCT06515444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 hour PD program
Description: The professional development (PD) component is a 1-hour dose of activities targeting each of the eight SECs on which the curriculum focuses. The focus of PD is not to teach about SEC development in children but to develop SEC in teachers. Thus, this is an 8-hour PD program distributed throughout the academic year.
Study NCT06515444 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 hour PD program
Description: The professional development (PD) component is a 1-hour dose of activities targeting each of the eight SECs on which the curriculum focuses. The focus of PD is not to teach about SEC development in children but to develop SEC in teachers. Thus, this is an 8-hour PD program distributed throughout the academic year.
Study NCT05554874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields
Description: receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.
Study NCT05554874 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed electromagnetic fields
Description: Sham application will be applied with the same device without applying magnetic current.
Study NCT06039098 — intervention group
Intervention type: DEVICE
Intervention: DCS
Description: DCS monitoring of brain
Study NCT05011019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsules
Description: AL2846 is a multi-target receptor tyrosine kinase inhibitor.
Study NCT05436782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core strengthening exercises
Description: •Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
Study NCT05436782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: •Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
Study NCT06334978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic intervention
Description: The experimental group received the same treatment as the control group and one osteopathic intervention per week for the 21 days of the study (days 2, 9 and 16). Each session was performed on a different day from the conventional treatment to prevent interactions. The physiotherapist performed an osteopathic assessment involving a static/dynamic inspection and palpation and other osteopathic tests: Mitchell test, Quick Scanning, standing flexion (Piedallu) test, Gillet test, sphenobasilar synchondrosis (SBS) test, sutural palpation test and diaphragm test. Techniques used: the dog technique in flexion, scalene muscle energy technique, Jones' first rib adjustment, first rib trust in posterior subluxation, occipitomastoid thrust, Sutherland's posterior needle-scratch, SBS decompression, semi-direct thrust for the sacrum, Sutherland's sacrum, posterior occipital condyle thrust, SBS equilibration.
Study NCT06535061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: white noise
Description: The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
Study NCT05459168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Calm Meditation Smartphone App Feedback
Description: Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
Study NCT05459168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cancer-Specific Meditation App Prototype Design
Description: Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
Study NCT05459168 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cancer-Specific Meditation App Prototype
Description: Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
Study NCT06535061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white noise
Description: The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
Study NCT06100497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
Study NCT06100497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
Study NCT06100497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Mainly used for neoadjuvant treatment
Study NCT05213845 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spine flexion/extension active range of motion exercises
Description: Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
Study NCT06374602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Lenvatinib
Description: Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody. Lenvatinib is Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
Study NCT06094153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consume placebo (Maltodextrin) once daily before going to bed for 28 days
Study NCT06094153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMO 1
Description: Consume HMO 1 (Dietary supplement) once daily before going to bed for 28 days
Study NCT06094153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMO 2
Description: Consume HMO 2 (Dietary supplement) once daily before going to bed for 28 days
Study NCT04676516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
Study NCT04958629 — intervention group
Intervention type: OTHER
Intervention: familial hypercholesterolemia
Description: Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
Study NCT05984147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR108
Description: 3 Days dosing, and 4 days no dose in a week
Study NCT05588089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers.
Study NCT05078450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Lifters
Description: Participants will need to attend 12 hour long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
Study NCT06412315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
Study NCT06412315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
Study NCT06124599 — intervention group
Intervention type: OTHER
Intervention: Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period
Description: questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other
Study NCT06124599 — intervention group
Intervention type: OTHER
Intervention: Identification of symptoms of menstrual in control patient in the last three menstrual period
Description: questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...
Study NCT05452005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-αvβ6-BP
Description: Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
Study NCT06049433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention
Description: The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
Study NCT06025396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP-301
Description: Multiple ascending dose active
Study NCT06025396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple ascending dose comparator
Study NCT05787977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Feedback and Rhythmic Auditory Cue
Description: Patients were trained five times per week for eight weeks. After eight weeks of training the gait pattern and balance was evaluated by the gait parameters, 6min Walk test, Pediatric Balance Scale and Berg balance scale.
Study NCT06225778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6-week online exercise group
Study NCT05852587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.
Study NCT05852587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.
Study NCT05974345 — intervention group
Intervention type: DRUG
Intervention: Inclisiran sodium
Description: Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
Study NCT05974345 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
Study NCT05974345 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe
Description: Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.
Study NCT05974345 — intervention group
Intervention type: DRUG
Intervention: Evolocumab
Description: Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
Study NCT04777682 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound, double balloon enteroscopy
Description: compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
Study NCT06049433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: On-Demand + Discussion board (DB)
Description: Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
Study NCT06049433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Arm 2
Description: The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)
Study NCT06049433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: On Demand (OD) + Video Conference (VC)
Description: on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
Study NCT06049433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Arm 3
Description: The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
Study NCT05658172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Determination of tumormarkers (CA27.29, CEA, CA125)
Description: CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
Study NCT05658172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Determination of CTC levels
Description: CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
Study NCT05658172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Determination of ctDNA levels
Description: Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
Study NCT05658172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Biobanking of blood samples
Description: To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
Study NCT05660265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4172239D
Description: Different strength of GSK4172239D will be administered in different cohorts.
Study NCT06049433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: On Demand (OD) + Video Conference (VC)
Description: Access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC)
Study NCT05908149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole Splint
Description: Insole splint used in 'Pes equinus' in patients with hemiplegia
Study NCT05961228 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: Three different posture with and without correction according to the Schroth method
Study NCT05959018 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Arrow Three-Lumen Central Venous Catheter
Description: Participants in the Non-impregnated CVC arm will receive Arrow Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
Study NCT05959018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter
Description: Participants in the Antimicrobial-impregnated CVC arm will receive Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use